| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
| ln Vitro |
KC7F2 (0-80 μM; 6 hours) potently reduces HIF-1α protein levels in a dose-dependent manner under hypoxic conditions; HIF-1α levels were significantly reduced at a concentration of 20 μM [Conditions [1]. KC7F2 (15-25 μM; 0-72 hours) exhibits clear dose-responsive cytotoxicity with IC50 values of approximately 15-25 μM, depending on the cell line, and this effect is more severe under hypoxic conditions. The rate at which HIF-1α protein regulation occurs is unaffected by KC7F2 [1]. While HIF-1α mRNA regulation is not inhibited by KC7F2, its protein production is [1]. The eukaryotic initiation regulator 4E-binding protein 1 (4EBP1) is regulated by KC7F2 [1]. Cell
|
|---|---|
| Cell Assay |
Cell cytotoxicity assay [1]
Cell Types: MCF7 cells, LNZ308 cells, A549 cells, U251MG cells, LN229 cells Tested Concentrations: 15–25 μM Incubation Duration: 0-72 hrs (hours) Experimental Results: Cytotoxicity is more obvious in tumors phosphorylated [1]. Cell lines compared to normal cells. Cell viability assay[1] Cell Types: LN229 Cell Tested Concentrations: 6 hrs (hours) Incubation Duration: 0 μM, 5 μM, 7.5 μM, 10 μM, 15 μM, 20 μM, 30 μM, 40 μM, 60 μM, 80 μM Experimental Results: Reduction HIF-1α protein levels were dose-dependent. |
| References |
[1]. Narita T, et al. Identification of a novel small molecule HIF-1alpha translation inhibitor. Clin Cancer Res. 2009 Oct 1;15(19):6128-6136.
|
| Molecular Formula |
C16H16CL4N2O4S4
|
|---|---|
| Molecular Weight |
570.38
|
| CAS # |
927822-86-4
|
| SMILES |
ClC1C([H])=C([H])C(=C([H])C=1S(N([H])C([H])([H])C([H])([H])SSC([H])([H])C([H])([H])N([H])S(C1C([H])=C(C([H])=C([H])C=1Cl)Cl)(=O)=O)(=O)=O)Cl
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 32 mg/mL (~56.10 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (4.38 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.38 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7532 mL | 8.7661 mL | 17.5322 mL | |
| 5 mM | 0.3506 mL | 1.7532 mL | 3.5064 mL | |
| 10 mM | 0.1753 mL | 0.8766 mL | 1.7532 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
